The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).
Patients with solid masses (diameter > 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.
Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT/MRI).
Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.
Signed informed consent form.
Patients with other active malignant tumors
Patients with coagulation dysfunction (PLT 50,000/mm3, INR > 1.5; roughly estimated, INR > 1.5 is approximately equivalent to PT > 18 seconds)
Pregnant women
Patients with hemorrhagic diseases